We cover AstraZeneca’s decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.
This slideshow shows drug information for Viltepso. Click here for the complete Viltepso monograph.
Positive links seen for dietary and circulating vitamin C with muscle mass in middle- and older-aged adults.
Casimersen is a phosphorodiamidate morpholino oligomer that works by binding to exon 45 of dystrophin pre-mRNA.
The application is supported by data from the multicenter, double-blind, placebo-controlled phase 2/3 SELECT-AXIS 1 study.
Viltepso is available through specialty distributors and specialty pharmacy providers.
Viltolarsen is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomers subclass.
The FDA has granted Fast Track designation to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin; Sarepta Therapeutics) for the treatment of Duchenne muscular dystrophy (DMD).
The FDA has granted Orphan Drug designation to VTA-110 (Vita Therapeutics) for the treatment of Duchenne muscular dystrophy (DMD).
Office visits with prescribed SMR nearly doubled; tripling in visits for continued SMR drug therapy.
